Discussion
Vertero Therapeutics has completed patient enrollment in a Phase 1b clinical trial testing VT-5006, an experimental treatment designed to target gut-related mechanisms believed to contribute to Parkinson’s disease. The Phase 1b study (NCT07310264) includes 24 adults with early- or moderate-stage Parkinson’s. It will assess the treatment’s safety…
